[go: up one dir, main page]

WO2014111790A3 - Stable transdermal pharmaceutical drug delivery system comprising rivastigmine - Google Patents

Stable transdermal pharmaceutical drug delivery system comprising rivastigmine Download PDF

Info

Publication number
WO2014111790A3
WO2014111790A3 PCT/IB2014/000029 IB2014000029W WO2014111790A3 WO 2014111790 A3 WO2014111790 A3 WO 2014111790A3 IB 2014000029 W IB2014000029 W IB 2014000029W WO 2014111790 A3 WO2014111790 A3 WO 2014111790A3
Authority
WO
WIPO (PCT)
Prior art keywords
rivastigmine
delivery system
drug delivery
pharmaceutical drug
transdermal pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/000029
Other languages
French (fr)
Other versions
WO2014111790A2 (en
Inventor
Abhay Sadashiv SAPRE
Ashok DEWANGAN
Amit Kumar SOLANKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Technologies Ltd
Original Assignee
Zydus Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Technologies Ltd filed Critical Zydus Technologies Ltd
Publication of WO2014111790A2 publication Critical patent/WO2014111790A2/en
Publication of WO2014111790A3 publication Critical patent/WO2014111790A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which is free from an antioxidant. In particularly, the present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which provides an enhanced absorption of drug through skin, and remains stable during a longer storage period. In addition, the present invention relates to a method of treatment of mild to moderate dementia of alzheimer's type and mild to moderate dementia of parkinson's type diseases.
PCT/IB2014/000029 2013-01-15 2014-01-14 Stable transdermal pharmaceutical drug delivery system comprising rivastigmine Ceased WO2014111790A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN128MU2013 2013-01-15
IN128/MUM/2013 2013-01-15

Publications (2)

Publication Number Publication Date
WO2014111790A2 WO2014111790A2 (en) 2014-07-24
WO2014111790A3 true WO2014111790A3 (en) 2014-10-23

Family

ID=50114434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/000029 Ceased WO2014111790A2 (en) 2013-01-15 2014-01-14 Stable transdermal pharmaceutical drug delivery system comprising rivastigmine

Country Status (1)

Country Link
WO (1) WO2014111790A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088898A1 (en) * 2014-12-05 2016-06-09 株式会社 ケイ・エム トランスダーム Adhesive sheet for attachment to skin and percutaneous absorption preparation using same
EP4122460A1 (en) * 2015-01-09 2023-01-25 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
TWI741168B (en) * 2017-04-28 2021-10-01 日商日東電工股份有限公司 Transdermal absorption preparation
KR102823139B1 (en) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 Rivastigmine patch for long-term administration
KR102710072B1 (en) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 Rivastigmine patch for long-term administration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
CA2817461A1 (en) * 2010-12-14 2012-06-21 Acino Ag Transdermal therapeutic system for administering an active substance
WO2012087047A2 (en) * 2010-12-24 2012-06-28 Samyang Biopharmaceuticals Corporation Percutaneous absorption preparation containing rivastigmine
US8338486B2 (en) * 2004-11-23 2012-12-25 Adamas Pharmaceuticals, Inc. Methods for the treatment of CNS-related conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
PT1670433E (en) 2003-10-10 2012-02-08 Ferring Bv Transdermal pharmaceutical formulation for minimizing skin residues
TWI389709B (en) 2005-12-01 2013-03-21 Novartis Ag Transdermal therapeutic system
KR101892764B1 (en) 2010-07-21 2018-08-28 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Transdermal adhesive compositions, devices, and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338486B2 (en) * 2004-11-23 2012-12-25 Adamas Pharmaceuticals, Inc. Methods for the treatment of CNS-related conditions
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
CA2817461A1 (en) * 2010-12-14 2012-06-21 Acino Ag Transdermal therapeutic system for administering an active substance
WO2012087047A2 (en) * 2010-12-24 2012-06-28 Samyang Biopharmaceuticals Corporation Percutaneous absorption preparation containing rivastigmine

Also Published As

Publication number Publication date
WO2014111790A2 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
HK1211475A1 (en) Combination therapy
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
IN2015DN01023A (en)
AU2017312811A8 (en) Liquid naloxone spray
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
EP3162804A8 (en) New benzodiazepine derivative and use thereof
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
PH12019501785A1 (en) Intranasal composition comprising betahistine
WO2013038200A3 (en) Neurodevelopmental disorders
HK1208356A1 (en) Methods of maintaining, treating or improving cognitive function
PL3085383T3 (en) A pharmaceutical composition comprising erythropoietin and ceftriaxone and a use thereof in the manufacture of a medicament for the treatment of parkinson's disease dementia
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
WO2018084817A3 (en) A new form of active agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14704888

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14704888

Country of ref document: EP

Kind code of ref document: A2